By


Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies

A highly potent panel of VNARs against the SARS-CoV-2 spike protein has been isolated

Neutralization of SARS-CoV-2 was demonstrated in in vitro infectivity assays

In vitro blocking activities were also found against the N501Y and E484K mutants

See more here

By


Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics 

  • Under the terms of the intended acquisition:  
    • Adhera will continue clinical development of MLR-1019
    • Melior Pharmaceuticals will receive Adhera stock plus royalties

See more here

By


Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer

Former chief medical officer of MyoKardia to lead clinical development at Renovacor 

See more here

By


Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern

– Additional $4.3 million in funding brings total DOD funding to $17.6 million.

– Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein.

– Neutralizes South Africa (B.1.351) and UK (B.1.1.7) in live virus testing and Brazil (P.1) and California (B.1.429, also containing B.1.427 mutations) in pseudovirus testing, all of which are CDC-designated “Variants of Concern.”

– Binds to several mutations, including E484Q and L452R, which are associated with the India variant (B.1.617) in mechanistic testing.

See more here

By


Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research

See more here

By


Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer’s Disease in Persons with Down Syndrome

See more here

By


Immunome Reports First Quarter 2021 Financial Results

– IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 “variants of concern” in preclinical testing, progressing towards IND filing –

– IMM-ONC-01: Advanced proprietary antibody against IL-38, a novel innate immune checkpoint, into IND-enabling studies –

– Dennis Giesing, Ph.D. appointed as Chief Development Officer and Corleen Roche appointed as Chief Financial Officer –

– Raised $27 million in gross proceeds in a private placement –

See more here

By


Venatorx Pharmaceuticals’ Novel Antibiotic Pipeline Addresses the Next Pandemic: Superbugs

Company to Watch – Venatorx Pharmaceuticals  

See more here